

Iconovo's new inhaler ICOPre to be presented at RDD 2021 workshop

Iconovo's new prefilled dual cavity dry powder inhaler will be publicly presented for the first time at RDD 2021 (May 4 – 7th). The design, different features and the development process of ICOPre® will be displayed at a workshop at the meeting. Iconovo explains how an integrated process can accelerate the product development to arrive at a complete inhalation product bioequivalent to Ellipta® including both the inhaler and a powder formulation. Iconovo applies a parallel development process for all generic Ellipta products and plans to out-license the whole portfolio of generic Ellipta products in ICOPre.

ICOPre has been developed in Iconovo's laboratory by its own specialists in inhaler engineering, powder formulation and analytical characterization. The expertise is reflected in excellent in-vitro equivalence for ICOPre achieved already after less than 12 months of development.

The Ellipta portfolio represents a major commercial opportunity with forecasted sales of USD 4.9 billion in 2025. However, the Ellipta inhaler is protected by several patents lasting until 2030, protecting many portfolio products longer than the drug substance patents. Iconovo decided to develop a proprietary internal design with a unique injection molded disk and cavity opening to go free from these patents. Not only will any company launching ICOPre avoid the infringement risk but also earn a patent protection for almost 20 years. But Iconovo did not stop here and has given it a clean attractive Scandinavian exterior design. More information about the ICOPre opportunity can be found at iconovo.se.

The presentation at RDD is by CTO Dr. Orest Lastow, the founder and inventor of the inhalers from Iconovo and can be viewed as an on-demand video by participants at RDD.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Image Attachments

[ICOpres Open Lid No Dropshadow](#)

Attachments

[Iconovo's new inhaler ICOpres to be presented at RDD 2021 workshop](#)